key: cord-0776558-om1nyhh1
authors: Méndez, Raúl; Balanzá‐Martínez, Vicent; Luperdi, Sussy C.; Estrada, Itziar; Latorre, Ana; González‐Jiménez, Paula; Bouzas, Leyre; Yépez, Katheryn; Ferrando, Ana; Reyes, Soledad; Menéndez, Rosario
title: Long‐term neuropsychiatric outcomes in COVID‐19 survivors: A 1‐year longitudinal study
date: 2021-09-26
journal: J Intern Med
DOI: 10.1111/joim.13389
sha: 485b093a0f4849cf6a6d54035bbfae4d67bf7b37
doc_id: 776558
cord_uid: om1nyhh1

nan

This is an observational longitudinal study in a large tertiary care hospital in Valencia (Spain) with laboratory confirmed SARS-CoV-2 infection hospitalised patients between 8 March and 25 April 2020. Exclusion criteria included patients aged ≥85 or <18 years, non-Spanish speaking subjects, nursing-home residents, pre-existing dementia, pre-existing or cognitive decline under evaluation, previous brain injury with cognitive sequelae, current alcohol/substance use disorder (except for nicotine) and previously lifetime history of major psychiatric disorders. The Biomedical Research Ethics Committee of La Fe University and Polytechnic Hospital reviewed and approved the study (2020-280-1). All recruited patients were contacted by telephone 2 (±1) and 12 (±1) months after the date of hospital discharge. A battery of standardised instruments validated in the Spanish general population was administered by telephone at 2 and 12 months including (i) immediate verbal memory and learning, delayed verbal memory, semantic verbal fluency and working memory (executive function) for the cognitive functioning; (ii) subjective cognitive complaints; (iii) anxiety, depression and post-traumatic stress disorder (PTSD) for the psychiatric morbidity and (iv) QoL. Neurocognitive Raúl Méndez, Vicent Balanzá-Martínez and Sussy C. Luperdi contributed equally. dysfunction was pre-defined as impairment in any of the four neuropsychological tests after adjusting for age and education level. Psychiatric morbidity was pre-defined as a positive screening in any of the three questionnaires assessing psychiatric morbidity. Additional information on standardised instruments is provided in the Supplemental file.

A total of 179 patients at 2 months and 171 (95.5% retention rate) at 12 months completed the assessments. The results obtained at 2 months have been previously published [6] . Table 1 describes the main baseline characteristics. Briefly, partic-ipants´age ranged from 23 to 82 years and 99 (57.9%) were male. Of them, 94 (55%) had at least one comorbidity. Additional information on education, clinical severity, analytical parameters, respiratory support, treatments and clinical outcomes are provided on Table 1 .

At 12 months, 73.7% of the patients had at least one persistent symptom according to a standardised symptom questionnaire, listed as follows: fatigue (48.5%), memory complaints (32.2%), arthromyalgia (26.9%), dyspnoea (25.7%), headache (15.8%), chest pain (7.6%), paraesthesia (7%), sputum production (7%), cough (5.3%), anosmia (5.3%), ageusia/dysgeusia (2.3%), fever (1.2%) and tremors (1.2%).

Twenty-four per cent of patients self-reported having some degree of impaired cognition according to the cognitive complaints' questionnaire (11.7% impaired memory function and 12.3% moderate or severe memory impairment), whilst 53.8% and 22.2% of patients had normal and optimal memory function, respectively. Neurocognitive dysfunction and psychiatric morbidity were found in 80 (46.8%) and 77 (45%) patients, respectively. The most affected cognitive domain was semantic verbal fluency (32.7%) followed by immediate verbal memory/learning (20.5%), working memory/executive function (12.3%) and delayed verbal memory (7.6%). The most prevalent psychiatric 

This is the first longitudinal study to simultaneously evaluate cognitive, psychiatric and QoL domains and COVID-19 long-lasting attributable symptoms in survivors in the long term. Before the COVID-19 pandemic, mental and cognitive problems had been reported in intensive care unit (ICU) survivors from different causes [7, 8] . Nevertheless, these problems in non-critical care patients are underdiagnosed and their long-term prevalence in COVID-19 is unknown. We found 46.8% of patients with cognitive impairment and 45% with psychi-atric morbidity at 1 year. Brain fog or long-COVID causes are to elucidate and might comprise inflammation, endothelial damage, autoimmunity, social stressors and others [9] . These results further support the long-lasting impact of COVID-19 on patients' QoL and health, specifically brain/mental health. Limitations of the study include the singlecentre design, the lack of data on neuropsychiatric outcomes previous to COVID-19 and on functions other than cognitive or psychiatric comorbidity [10] .

In summary, declined cognitive function, psychiatric morbidity and low QoL are prevalent in moderate to severe COVID-19 survivors 1 year after hospital discharge. This data await confirmation by further prospective studies in other regions. Meanwhile, health policies should be designed to address these long-term problems. A multidisciplinary approach that includes neurocognitive rehabilitation and psychiatric evaluation and treatments should be offered to indicated patients.

This study was approved by the Ethics Committee of the Hospital Universitario y Politécnico La Fe (2020-280-1).

We are indebted to all patients and colleagues for their cooperation and assistance in this study. Always in our memory those who are no longer among us due to this pandemic.

All authors have accepted the publication of the manuscript.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

There was non-specific funding for this study. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. 

The authors have no related competing interests to declare.

Conceptualisation and study design: R. 

Post-acute COVID-19 syndrome

COVID-19 rapid guideline: managing the longterm effects of COVID-19

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

A quantitative and qualitative study on the neuropsychiatric sequelae of acutely ill COVID-19 inpatients in isolation facilities

Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors

New physical, mental, and cognitive problems 1 year after ICU admission: a prospective multicenter study

Physical and cognitive performance of patients with acute lung injury 1 year after initial trophic versus full enteral feeding EDEN Trial follow-up

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Comparison of brain activation patterns during olfactory stimuli between recovered COVID-19 Patients and healthy controls: a functional near-infrared spectroscopy (fNIRS) study